产品名称：Human IgE Antibody (Ligelizumab, Research Use)
产品编号：NBR-0719
针对靶点：IgE
抗体药商品名：Ligelizumab
抗体药描述：Ligelizumab (QGE031) is a more recent humanized anti-IgE antibody developed by Novartis. It is also directed against Cε3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139 pM (as compared to the KD of omalizumab, ~6–8 nm). The first clinical results of ligelizumab treatment indicated that this antibody can reduce free-IgE and basophil FcεRI with an efficiency superior to that of omalizumab (NCT01716754). 产品外观：Transparent Liquid
分子量：~150kDa
CAS：N/A
溶解度：Water; PBS, TBS Buffer等
表达系统：CHO Expressed
抗体亚型：Ab. Isotype - IgG

  Gene Name: IGHE
Synonyms: N/A
Target Description: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells.
Ensembl: ENSG00000211891
Uniprot:  P01854